0 items - $0.00 0
Complete Omics
0 items - $0.00 0
Complete Omics

Selected Important Publications by Complete Omics

Close

Valid-NEO®
The World’s Only Platform for Direct Ultra-Sensitive Neoantigen Detection

SCIENCE

Breaking the “Undruggable”: TP53 Neoantigens Identified by Valid-NEO®

Science2021 Mar 5; 371(6533): eabc8697.

Valid-NEO

SCIENCE IMMUNOLOGY

Breaking the “Undruggable”: KRAS Neoantigens Identified by Valid-NEO®

Science Immunology. 2021 Mar 1; 6(57): eabd5515.

Valid-NEO

SCIENCE ADVANCES

Valid-NEO® Unlocking a New Class of Cancer Targets-HERV Neoantigens

Science Advances. 2022 Jan 28; 8(4): eabj3671.

Valid-NEO

CANCERS

Valid-NEO®: A Clinical Platform Built to Directly Detect Rare Neoantigens

Cancers. 2022 Feb 28; 14(5): 1243.

Valid-NEO

BLOOD ADVANCES

Shared Leukemia Neoantigens Identified by Valid-NEO®

Blood Advances. 2022 Dec 9; 7(9): 1635–1649.

Valid-NEO

CANCER IMMUNOLOGY RESEARCH

First Direct Detection of Neoantigens: Valid-NEO® [Prototype]

Cancer Immunology Research. 2019 Nov; 7(11): 1748–1754.

Valid-NEO

JOURNAL FOR IMMUNOTHERAPY OF CANCER

Valid-NEO® Identifying Shared Neoantigens in Ovarian Cancer

Journal for Immunotherapy of Cancer. 2025 Aug 3; 13(8): e010099.

Valid-NEO

Biomarker and Liquid Biopsy (i.e. Complete360)

Benchmarking Mainstream Proteomics Platforms: Complete360 Reveals the Deepest Blood Proteome

bioRxiv [Preprint]. 2025 May 20: 2025.05.15.654311.
Systematic comparison across major mass spectrometry–based proteomics platforms demonstrating that Complete360 provides the deepest coverage of the human blood proteome.

Liquid Omics

First Clinical Application of Complete360: Deep Proteomics Reaches 10,000 Proteins per Patient

Cell. 2025 Aug 7; 188(16): 4225–4238.e12.
First clinical application of the Complete360 platform achieving ~10,000 proteins per patient sample in a CAR-NK therapy study.

Liquid Omics

Detecting the Nearly Undetectable: Ultra-Low-Abundance Detection by Complete360®

Science. 2026 Apr 23:eadz7118.
Complete360® Resolves an Exceptionally Low-Abundance Phosphorylation Event Beyond Conventional Detection Limits.

Biomarkers

A Paradigm Shift in Cancer Biomarkers: An Early Prototype of Complete360

Proceedings of the National Academy of Sciences (PNAS). 2011 Feb 8; 108(6): 2444–2449.
Targeted clinical proteomics enabling ultra-sensitive quantification of mutant cancer biomarkers from single cells and body fluids.

Liquid Omics

Ultra-Sensitive Targeted Proteomics: An Early Prototype of Complete360

Proceedings of the National Academy of Sciences (PNAS). 2017 Dec 19; 114(51): 13519–13524.
Recursive optimization of targeted proteomics demonstrating substantially higher sensitivity than profiling-level platforms.

Liquid Omics

Situationally Optimized Proteomics with Complete360 Reveals DLAT Methylation in Cancer Metabolism

Nature Communications. 2025 Jan 30; 16(1): 1191.
Application of the Complete360 platform enabling situational-awareness–guided targeted detection of a protein and its PTM, revealing DLAT methylation controlling pyruvate dehydrogenase activity and prostate cancer growth.

Biomarkers